Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021).

Research & information: general --- MMP --- MMP2 --- MMP9 --- MMP7 --- MMP14 --- matrix metalloproteases --- PDAC --- pancreatic cancer --- Bowman–Birk inhibitor --- ranacyclin --- trypsin inhibitor --- structure–activity relationship --- synergistic effect --- Gentamicin --- matrix metalloproteinase --- extracellular matrix --- nuclei --- cancer --- apoptosis --- immune response --- cysteine protease inhibitor --- stefin --- signal peptide --- parasite --- phylogenetic analysis --- diversification --- protein structure --- vascular endothelial growth factors (VEGFs) --- VEGF-A --- PlGF --- VEGF-B --- VEGF-C --- VEGF-D --- angiogenesis --- lymphangiogenesis --- CCBE1 --- proteases --- ADAMTS3 --- plasmin --- cathepsin D --- KLK3 --- prostate-specific antigen (PSA) --- thrombin --- wound healing --- metastasis --- proteolytic activation --- vascular biology --- lymphedema --- MMP --- MMP2 --- MMP9 --- MMP7 --- MMP14 --- matrix metalloproteases --- PDAC --- pancreatic cancer --- Bowman–Birk inhibitor --- ranacyclin --- trypsin inhibitor --- structure–activity relationship --- synergistic effect --- Gentamicin --- matrix metalloproteinase --- extracellular matrix --- nuclei --- cancer --- apoptosis --- immune response --- cysteine protease inhibitor --- stefin --- signal peptide --- parasite --- phylogenetic analysis --- diversification --- protein structure --- vascular endothelial growth factors (VEGFs) --- VEGF-A --- PlGF --- VEGF-B --- VEGF-C --- VEGF-D --- angiogenesis --- lymphangiogenesis --- CCBE1 --- proteases --- ADAMTS3 --- plasmin --- cathepsin D --- KLK3 --- prostate-specific antigen (PSA) --- thrombin --- wound healing --- metastasis --- proteolytic activation --- vascular biology --- lymphedema

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021).

MMP --- MMP2 --- MMP9 --- MMP7 --- MMP14 --- matrix metalloproteases --- PDAC --- pancreatic cancer --- Bowman–Birk inhibitor --- ranacyclin --- trypsin inhibitor --- structure–activity relationship --- synergistic effect --- Gentamicin --- matrix metalloproteinase --- extracellular matrix --- nuclei --- cancer --- apoptosis --- immune response --- cysteine protease inhibitor --- stefin --- signal peptide --- parasite --- phylogenetic analysis --- diversification --- protein structure --- vascular endothelial growth factors (VEGFs) --- VEGF-A --- PlGF --- VEGF-B --- VEGF-C --- VEGF-D --- angiogenesis --- lymphangiogenesis --- CCBE1 --- proteases --- ADAMTS3 --- plasmin --- cathepsin D --- KLK3 --- prostate-specific antigen (PSA) --- thrombin --- wound healing --- metastasis --- proteolytic activation --- vascular biology --- lymphedema

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The conversion of milk to different dairy products is a technological process that has been in use for hundreds of years. Most dairy products are produced at a commercial scale using traditional methods and therefore, many efforts have been made to introduce novel technologies in their manufacture for improving their quality in general. More specifically, modern processing approaches may be used with the aim to develop new dairy products, to extend their shelf life, to change their textural properties, to ensure their safety or to increase their nutritional and health value. High Hydrostatic Pressure treatment, Ultrasound Processing, Pulse Electric Field treatment and Membrane Processing are some of these novel processes, which may be used in milk, yoghurt and other dairy product processing. Moreover, new dairy ingredients can be produced after enrichment with milk components, while modern analytical methods, such as nuclear magnetic resonance (NMR) and X-ray microtomography, are used for testing the main properties of dairy products.

recrystallization --- food hydrocolloids --- methods for crystal structure evaluation --- high hydrostatic pressure --- whey protein hydrolysates --- sheep milk --- yoghurt --- ACE inhibitory activity --- gel properties --- heat stability --- traditional yoghurt starter --- biofunctionality --- alpha-lactalbumin (α-Lac) --- beta-lactoglobulin (β-Lg) --- high pressure processing (HPP) --- pasteurization --- ready-to-feed (RTF) infant formula --- milk phospholipids --- buttermilk --- life-cycle assessment --- carbon footprint --- supercritical fluid extraction --- membrane separation --- microfiltration --- ovine milk --- bovine milk --- casein fractions --- alkaline phosphatase --- cathepsin D --- milk renneting properties --- probiotics --- viability model --- high-pressure processing --- rheology --- sensory quality --- fermented dairy beverage --- antioxidant capacity --- microbial inactivation --- image analysis --- high pressure processing --- total phenolic content --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Lysosomal storage disorders are a heterogenoeus group of rare genetic conditions affecting worldwide population and often exhibiting severe clinical manifestations. During the last two decades, the joined collaboration between scientists and clinicians has allowed to offer valuable therapeutic options to affected patients. Therefore, the tight connection between basic science and clinical medicine represents the gold standard approach to these disorders. In this context, the present book collects a piece of current scientific advances in the knowledge of disease pathogenesis and in the development of novel diagnostic and therapeutic strategies for some of these diseases. Altogether, these articles define and recapitulate which essential steps are required during the clinical management of a rare inherited disorder and describe forthcoming advances and a breakthrough in the field of lysosomal diseases.

mucopolysaccharidosis IIIB --- quantitative proteomics --- NAGLU --- lysosomes --- Gaucher disease --- bone involvement --- enzyme replacement therapy --- substrate reduction therapy --- Osteoimmunology --- RANK/RANKL --- Osteopontin --- MIP-1β --- mucolipidosis II --- sortilin --- TGF-beta --- cathepsin D --- Fabry disease --- alpha-galactosidase A --- endocytosis --- lysosome --- IGF2R/M6P --- clathrin --- chloroquine --- lysosomal diseases --- precision medicine --- pharmacological chaperones --- gene therapy. --- Pompe disease --- lysosomal targeting --- autophagy --- gene therapy --- muscle --- satellite cells --- rhGAA --- glycogen --- lysosomal α-glucosidase --- GAA biomarker --- Gaucher Disease --- Wnt/β-catenin --- Dkk1 --- Wnt3a --- iPSC --- neuronopathy --- Krabbe disease --- Twitcher mouse --- psychosine --- visual system --- visual cortex --- astrogliosis --- mucopolysaccharidosis type I --- Hurler syndrome --- hematopoietic stem cell transplantations --- animal models --- experimental therapies --- axon guidance --- lysosomal storage disorders --- neuronal circuit --- α-galactosidase A --- A4GALT --- globotriaosylceramide (Gb3) --- globotriaosyl-sphingosine (lysoGb3) --- pharmacological chaperone therapy --- exosomes --- endocytic pathways --- neurodegenerative disease --- Parkinson disease --- lysosomal storage disorder --- viral vectors --- newborn screening --- variant interpretation --- second tier test --- tandem mass spectrometry --- lyso-Gb3 --- dried blood spot --- GLA gene --- globotriaosylsphingosine --- biomarkers

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This special issue brings together cutting edge research and insightful commentary on the currentl state of the Cancer Nanomedicine field.

Technology: general issues --- antibody drug conjugate (ADC) --- PD-L1 --- tumor spheroid disruption --- immune modulation --- doxorubicin --- graphene oxide --- adsorption --- cathepsin D --- cathepsin L --- anti-metastatic enzyme cancer therapy --- nanoparticles --- targeted delivery system --- siRNA --- osteopontin --- mammary carcinoma --- mesenchymal stem cells (MSCs) --- TAT peptide --- PLGA --- paclitaxel --- nano-engineered MSCs --- orthotopic lung tumor model --- intracranial glioma --- immunotherapy --- CPMV --- viral nanoparticles --- in situ vaccine --- albumin nanoparticles --- microbubble --- ultrasound --- theranostics --- hepatocellular carcinoma --- VX2 tumor --- intra-arterial chemotherapy --- lung cancer --- nanomedicine --- clinical status --- cancer therapy --- breast cancer --- cell signaling --- active targeting --- passive targeting --- EPR effect --- oncogenes --- nanoparticle --- drug delivery --- ligand --- tumor targeting --- biodistribution --- Mesoporous silica nanoparticle --- drug delivery system --- target treatment --- lanthanide metal --- hyaluronic acid --- hyaluronidase --- drug combination --- everolimus --- dual-targeting --- magnetic nanoparticles --- monoclonal antibodies --- nanostructured lipid carrier --- platelet membrane --- biomimicry --- plasmonic photothermal therapy --- gold nanorods --- surgery --- bleeding --- dogs --- cats --- stimuli-responsive --- DOX --- SN38 --- CSCs --- single-walled carbon nanotubes --- chirality separation --- NASH --- drug-gene delivery --- near IR hyperspectral imaging --- plasmonics --- copper --- VEGF --- glioblastoma --- differentiated neuroblastoma --- peptidomimetics --- real-time quantitative polymerase chain reaction (qPCR) --- actin --- combinatorial therapy --- anticancer and antibacterial activity --- temoporfin --- drug-in-cyclodextrin-in-liposome --- hybrid nanoparticles --- multicellular tumor spheroids --- cyclodextrins --- photodynamic therapy article --- yet reasonably common within the subject discipline --- antitumor strategy --- biomimetic core–shell nanoparticles --- NK cell-derived exosomes --- folate receptor --- albumin nanoparticle --- microfluidic --- cabazitaxel --- polydopamine nanoparticles --- size --- cytotoxicity --- iron affinity --- FA-DABA-SMA --- self-assembly --- oncogenic proteins --- intracellular disruption --- folic receptor alpha --- pancreatic cancer --- parvifloron D --- albumin --- erlotinib --- photodynamic therapy --- lipid nanoparticles --- tumor vectorization --- verteporfin --- ovarian carcinomatosis --- spheroids --- integrin --- RGD peptide --- cancer diagnosis --- radiotherapy --- hyperthermia therapy --- biomimetic --- nanocarrier --- membrane-wrapped --- cancer --- targeted delivery --- photothermal therapy --- imaging --- cancer nanomedicine --- tumor microenvironment --- nano–bio interactions --- clinical translation --- magnetic nanowires --- magnetic hyperthermia --- magnetic actuation --- magnetic drug targeting --- titanate nanotubes --- gold nanoparticles --- vectorization --- colloidal stability --- docetaxel --- prostate cancer --- mangiferin --- anti-topoisomerase activity --- extracellular vesicles --- exosomes --- chemico-physical functionalization --- loading --- translational medicine --- nanotechnology: bioengineering --- anacardic acid --- mitoxantrone --- targeted drug delivery --- liposomes --- melanoma --- apoptosis --- ascorbic acid --- angiogenesis --- epithelial-to-mesenchymal transition --- hypoxia --- immunosuppression --- metabolism --- nanotherapeutics --- tumour microenvironment --- DNA origami --- liposome --- remote loading --- acute toxicity --- organoids --- magnetic silica-coated iron oxide nanochains --- photothermal treatment --- hyperthermia --- collagen --- cellular microenvironment --- lymphadenectomy --- magnetometer --- sentinel lymph node dissection --- SPION --- superparamagnetic iron oxide nanoparticles --- Vδ2 T cells --- zoledronic acid --- polymeric nanoconstruct --- anti-tumor immunity --- colorectal carcinoma --- β-cyclodextrin nanosponges --- BALB-neuT mice --- brain tumours --- glioma --- blood brain barrier --- polymeric nanoparticles --- PEGylation --- dioleoylphosphatidylethanolamine --- poly(hydroxyethyl acrylate-co-allyl methyl sulfide) copolymer --- folate --- oxidation-sensitive release --- cellular interaction --- in vitro anti-cancer activity --- triple negative breast cancer --- organotin --- mesoporous silica nanoparticles --- MDA-MB-231 --- theranostic nanomaterials --- nanobiotechnology --- molecular imaging --- nanosystems --- nanomicelles --- ovarian cancer --- tumour targeting --- chemotherapeutics --- riboflavin --- vitamin B2 --- nanomedicines --- secondary structure --- mixed micelle --- pH responsive --- targeted therapy --- anti-cancer --- shear stress --- flow --- in vitro --- therapeutics --- diagnostics --- Immunotherapy